Stoke Therapeutics (NASDAQ:STOK) Trading Up 7.6%

Stoke Therapeutics, Inc. (NASDAQ:STOKGet Rating) shares were up 7.6% during mid-day trading on Thursday . The stock traded as high as $16.65 and last traded at $16.65. Approximately 437 shares were traded during mid-day trading, a decline of 100% from the average daily volume of 168,149 shares. The stock had previously closed at $15.47.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald decreased their price target on Stoke Therapeutics from $68.00 to $38.00 in a research note on Thursday, May 26th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Stoke Therapeutics currently has an average rating of “Buy” and an average target price of $47.80.

Stoke Therapeutics Trading Up 2.7 %

The business has a 50-day moving average of $13.64 and a two-hundred day moving average of $16.95.

Stoke Therapeutics (NASDAQ:STOKGet Rating) last issued its quarterly earnings data on Tuesday, May 10th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of $0.61 by ($1.27). The company had revenue of $3.00 million during the quarter, compared to analyst estimates of $60.00 million. On average, analysts forecast that Stoke Therapeutics, Inc. will post -2.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of STOK. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Stoke Therapeutics during the 1st quarter worth $28,133,000. Wellington Management Group LLP acquired a new position in Stoke Therapeutics during the 1st quarter worth about $25,011,000. M28 Capital Management LP acquired a new position in Stoke Therapeutics during the 4th quarter worth about $12,646,000. Point72 Asset Management L.P. acquired a new position in Stoke Therapeutics during the 4th quarter worth about $5,614,000. Finally, Ally Bridge Group NY LLC acquired a new position in Stoke Therapeutics during the 4th quarter worth about $4,438,000. Institutional investors own 99.87% of the company’s stock.

Stoke Therapeutics Company Profile

(Get Rating)

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression.

Further Reading

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.